Yan Jiang, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jiang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A144060 · Current
Licensed to practise in California · since 2016 · expires 2028-01-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$60,356
Medicare paid this office $60,356 for 306 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 87 | $10,115 | $116 |
| Return visit (30+ min) | 65 | $8,121 | $102 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 24 | $5,897 | $236 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,484 | $109 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,752 | $117 |
See all 14 services
| New patient visit (45+ min) | 87 | $10,115 | $116 |
| Return visit (30+ min) | 65 | $8,121 | $102 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 24 | $5,897 | $236 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,484 | $109 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,752 | $117 |
| Long return visit (40+ min) | 21 | $3,568 | $155 |
| Biopsy of large bowel using a flexible endoscope | 28 | $2,995 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,340 | $156 |
| Short return visit (20+ min) | 30 | $2,084 | $69 |
| Study of esophagus to assess movement | 33 | $1,972 | $58 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,673 | $93 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 33 | $1,487 | $44 |
| Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | 12 | $776 | $65 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 30 | $147 | $4 |
Procedures Medicare counted
| Colonoscopy | 34 | More than 56% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 82 | More than 73% of doctors who do this |
Who their Medicare patients are
306 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 11% · Women 55% · Also on Medicaid 27% · Health risk score 1.71. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 72% · Diabetes 30% · Coronary heart disease 30% · Chronic kidney disease 25% · Atrial fibrillation 23% · Depression 22% · Heart failure 21% · Cancer 20% · COPD 19% · Stroke 10% · Dementia 9%.
The office billed $654,145, Medicare allowed $78,655 and paid $60,356; for 626 services of 41 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 306 | 626 | 73 | 1.71 | $654,145 | $60,356 |
| 2023 | 137 | 296 | 71 | 1.56 | $305,153 | $26,840 |
| 2022 | 152 | 291 | 68 | 1.97 | $238,142 | $25,082 |
| 2021 | 42 | 68 | 65 | 3.38 | $59,269 | $7,798 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| New patient visit (45+ min) | 50 | $5,617 | $112 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | $3,577 | $224 |
| Biopsy of large bowel using a flexible endoscope | 27 | $2,879 | $107 |
| New patient visit (60+ min) | 13 | $2,078 | $160 |
| Return visit (30+ min) | 16 | $1,997 | $87 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,781 | $99 |
| Long return visit (40+ min) | 11 | $1,661 | $128 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 14 | $568 | $41 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 31 | $158 | $5 |
2022: 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,984 | $208 |
| Biopsy of large bowel using a flexible endoscope | 42 | $4,048 | $90 |
| New patient visit (60+ min) | 16 | $2,339 | $146 |
| Return visit (30+ min) | 24 | $2,337 | $83 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,262 | $98 |
| Long return visit (40+ min) | 12 | $1,497 | $125 |
| Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | 15 | $1,043 | $70 |
| New patient visit (45+ min) | 12 | $977 | $81 |
| Short return visit (20+ min) | 11 | $682 | $57 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 19 | $159 | $8 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 21 | $105 | $4 |
Drugs they prescribed that Part D paid
$24,622
Pharmacies billed $24,622 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 253) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
194 generic and 59 brand-name prescriptions · $24,622 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 32 | $18,279 | $571 |
| Esomeprazole Magnesium | 15 | $1,131 | $75 |
| Omeprazole | 75 | $1,113 | $15 |
| Peg 3350-Electrolyte | 33 | $594 | $18 |
| Gavilyte-G | 22 | $339 | $15 |
See all 8 drugs
| Linzess | 32 | $18,279 | $571 |
| Esomeprazole Magnesium | 15 | $1,131 | $75 |
| Omeprazole | 75 | $1,113 | $15 |
| Peg 3350-Electrolyte | 33 | $594 | $18 |
| Gavilyte-G | 22 | $339 | $15 |
| Pantoprazole | 21 | $218 | $10 |
| Peg-3350 and Electrolytes | 11 | $206 | $19 |
| Famotidine | 21 | $102 | $5 |
Year by year
| 2024 | 253 | 123 | 0% (0) | 23% | $24,622 |
| 2023 | 154 | 92 | 0% (0) | 16% | $10,797 |
| 2022 | 85 | 58 | 0% (0) | 25% | $8,422 |
| 2021 | 22 | 14 | 0% (0) | None | $2,826 |
| 2020 | 19 | None | 0% (0) | None | $4,128 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Linzess | 12 | $6,483 | $540 |
| Peg 3350-Electrolyte | 30 | $669 | $22 |
| Gavilyte-G | 26 | $530 | $20 |
| Omeprazole | 36 | $458 | $13 |
| Pantoprazole | 15 | $129 | $9 |
2022: 2 drugs
| Gavilyte-G | 25 | $383 | $15 |
| Peg-3350 and Electrolytes | 16 | $203 | $13 |
Professional record
- NPI
- 1831585595
- Licence
- CA A144060California A144060: Current · expires 2028-01-31
- Trained
- New York University School of Medicine, 2015
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-04-09
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.